OSLO, Norway, June 23, 2021 /PRNewswire/ -- Photocure, The
Bladder Cancer Company, announces the publication of a study in the
journal Urologic Oncology. The study objective was to determine the
estimated budget impact to practices that incorporate blue light
cystoscopy (BLC®) with hexaminolevulinate HCl (HAL) for
the surveillance of non-muscle-invasive bladder cancer (NMIBC) in
the clinic setting.
The study utilizes real world data from a large Academic
Hospital Urology practice in the U.S. to estimate the net cost when
Blue Light Cystoscopy with Cysview® is utilized for
both surveillance and TURBT* in all NMIBC patients based on
National Medicare Reimbursement rates alone. The objective of this
budget impact model was to quantify the impact of using BLC with
HAL when used in patients who were undergoing cystoscopy for the
detection of NMIBC, including carcinoma in situ (CIS), among
patients suspected or known to have lesion(s). The model compared
the costs and outcomes of two different scenarios in NMIBC: white
light cystoscopy (WLC) in the office, followed by WLC during TURBT,
versus BLC in the office, followed by BLC during TURBT.In a
simulated facility with 50 newly diagnosed bladder cancer patients,
the model illustrates that the additional use of BLC in
surveillance identified 9 additional recurrences over two years
compared to WLC alone. Use of flexible BLC for surveillance
marginally increased costs to the practice, with a net difference
of $0.76 per cystoscopy over 2
years.
This study illustrates how the inclusion of BLC with Cysview
throughout the continuum of care in NMIBC patients results in
improved detection, and therefore improved patient risk
stratification, without impacting overall cost in a Hospital
outpatient setting.
"This model analyzes how incorporation of Blue Light
Cystoscopy with Cysview impacts the cost to a practice in the
continuum of care of NMIBC patients. We found that a practice's
patients could experience the benefits of earlier detection and
improved risk stratification without a significant cost burden
experienced by the practice. I believe future studies examining the
economic impact of Blue Light Cystoscopy with Cysview are warranted
and would further elucidate the direct and long-term cost benefits
in the diagnosis, treatment and management of NMIBC patients,"
said Dr. Stephen B. Williams, MD,
MS, FACS Chief of Urology, Professor (Tenured) of Urology and
Radiology, Robert Earl Cone Professorship, Director of Urologic
Oncology, Director of Urologic Research, Co-Director of the
Surgical Outcomes Research Division, and lead author of the
study.
Read the full article here:
https://www.sciencedirect.com/science/article/pii/S1078143921002313?dgcid=author
In December 2020, Photocure
communicated an abstract of this study, which was presented at the
SUO congress prior to the manuscript undergoing peer review for
publication: https://photocure.com/news/new-abstracts-on-the-use-of-blue-light-cystoscopy-with-cysview-presented-at-suo/
*TURBT: trans-urethral resection of bladder tumors
Note to editors:
All trademarks mentioned in this release are protected by law
and are registered trademarks of Photocure ASA
About Bladder Cancer
Bladder cancer ranks as the seventh most common cancer worldwide
with 1 720 000 prevalent cases (5-year prevalence
rate)1a, 573 000 new cases and more than
200 000 deaths annually in 2020.1b
Approx. 75% of all bladder cancer cases occur in
men.1 It has a high recurrence rate with an average of
61% in year one and 78% over five years.2 Bladder cancer
has the highest lifetime treatment costs per patient of all
cancers.3
Bladder cancer is a costly, potentially progressive disease for
which patients have to undergo multiple cystoscopies due to the
high risk of recurrence. There is an urgent need to improve both
the diagnosis and the management of bladder cancer for the benefit
of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive
bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC),
depending on the depth of invasion in the bladder wall. NMIBC
remains in the inner layer of cells lining the bladder. These
cancers are the most common (75%) of all BC cases and include the
subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the
cancer has grown into deeper layers of the bladder wall. These
cancers, including subtypes T2, T3 and T4, are more likely to
spread and are harder to treat.4
1 Globocan. a) 5-year prevalence / b)
incidence/mortality by population. Available at:
https://gco.iarc.fr/today, accessed [April
2021].
2 Babjuk M, et al. Eur Urol. 2019; 76(5):
639-657
3 Sievert KD et al. World J Urol
2009;27:295–300
4 Bladder Cancer. American Cancer
Society. https://www.cancer.org/cancer/bladder-cancer.html
About
Hexvix®/Cysview® (hexaminolevulinate
HCl)
Hexvix®/Cysview® is a drug that
preferentially accumulates in cancer cells in the bladder making
them glow bright pink during Blue Light Cystoscopy
(BLC®). BLC with Hexvix/Cysview improves the
detection of tumors and leads to more complete resection, fewer
residual tumors and better management decisions.
Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all other
markets. Photocure is commercializing Cysview/Hexvix directly in
the U.S. and Europe, and has
strategic partnerships for the commercialization of Hexvix/Cysview
in China, Canada, Chile, Australia and New
Zealand. Please refer to
https://photocure.com/partnering-with-photocure/our-partners/ for
further information on our commercial partners.
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative
solutions to improve the lives of bladder cancer patients. Our
unique technology, making cancer cells glow bright pink, has led to
better health outcomes for patients worldwide. Photocure is
headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information,
please visit us at www.photocure.com, www.hexvix.com,
www.cysview.com
For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com
David Moskowitz
Head of Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/photocure/r/new-article-published-in-urologic-oncology--macro-and-microeconomics-of-blue-light-cystoscopy-with-c,c3372413
The following files are available for download:
https://mb.cision.com/Main/17498/3372413/1435598.pdf
|
Release
|